In the rapidly evolving landscape of synthetic biology, the selection of an optimal biological host, or "chassis," is the foundational step that determines the success of any biomanufacturing endeavor. At CD BioGlyco, we recognize that simply inserting a genetic circuit into a cell is not enough. To achieve commercially viable yields of complex glycans, glycoproteins, or specialized metabolites, the underlying metabolic landscape of the host must be perfectly aligned with the desired biosynthetic pathway.
While traditional screening methods often rely on growth rates or end-product titers, which are "lagging indicators" of cellular performance, metabolomics provides a real-time, "leading indicator" view of the intracellular environment. By analyzing the complete set of small-molecule metabolites within a cell, we identify metabolic bottlenecks, redox imbalances, and energy limitations that would otherwise remain invisible. This approach allows us to rank and select chassis strains based on their actual metabolic fitness and readiness for large-scale production.
Key Technologies
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
This is our primary workhorse for identifying and quantifying a broad spectrum of polar and non-polar metabolites. The high sensitivity and specificity of LC-MS/MS allow us to detect low-abundance intermediates in glycosylation pathways, providing a detailed map of metabolic flux that informs strain selection.
Gas Chromatography-Mass Spectrometry (GC-MS)
For the analysis of volatile compounds and primary metabolic intermediates, such as organic acids and sugars, GC-MS offers unparalleled resolution and reproducibility. This technology is essential for assessing the core carbon metabolism of potential chassis strains.
Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR serves as a powerful complementary tool, offering non-destructive analysis and the ability to identify the absolute structure of unknown metabolites. It is particularly useful for quantifying high-abundance metabolites and performing stable isotope-labeled metabolic flux analysis (MFA).
Metabolomics: Mapping the Molecular Blueprint for Optimal Bioproduction
At CD BioGlyco, our service scope for metabolomics-based chassis strain screening is designed to navigate the complexities of cellular metabolism with surgical precision. We understand that a "one size fits all" approach does not work in synthetic glycobiology. Therefore, our service encompasses a wide range of development methods and technologies aimed at identifying the most efficient microbial, fungal, or mammalian chassis for your specific project.
The core of our service lies in untargeted and targeted metabolomics. Untargeted screening allows us to perform a global metabolic "fingerprinting" of various candidate strains under different environmental conditions. This is crucial during the initial screening phase, where we look for unexpected metabolic shifts or the accumulation of inhibitory byproducts. Once top candidates are identified, we transition to targeted metabolomics to quantify specific precursors required for glycan synthesis, such as nucleotide sugars (e.g., UDP-Glc, GDP-Man).
Furthermore, we implement MFA using stable isotopes like 13C. This allows us to move beyond static metabolite concentrations and actually measure the speed and direction of carbon flow through the cell. By understanding the flux distribution, we identify which strains naturally direct more carbon toward the desired product and which strains are "wasting" energy on biomass or secondary pathways.
Our scope also extends to multi-omics integration. We don't view metabolomics in isolation; we correlate metabolomic data with transcriptomic and proteomic profiles to provide a holistic view of the chassis. This integrated approach helps in identifying why certain strains perform better, allowing for rational engineering in subsequent steps. Whether you are working with Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, or mammalian cell lines like CHO, our service provides the data-driven insights needed to move forward with confidence.
Workflow
Initial Consultation and Design
Every project begins with a deep dive into the client's goals. We discuss the target molecule, the library of candidate strains, and the specific metabolic requirements. We then design a customized metabolomics study, selecting the appropriate analytical platforms and sampling time points.
Standardized Strain Cultivation
Strains are cultivated under highly controlled conditions, often utilizing our automated micro-fermentation systems. This ensures that any observed metabolic differences are due to the strain's genetic makeup rather than environmental noise.
Quenching and Metabolite Extraction
To capture a true "snapshot" of the cell, we utilize rapid quenching techniques (e.g., cold methanol) to instantly stop enzymatic activity. We then use optimized extraction protocols to ensure maximum recovery of both polar and non-polar metabolites.
High-Resolution Data Acquisition
Samples are analyzed using our state-of-the-art LC-MS/MS, GC-MS, or NMR platforms. We employ rigorous quality control (QC) measures, including the use of internal standards and technical replicates, to ensure the highest data integrity.
Advanced Bioinformatic Processing
Raw data is processed using proprietary and industry-standard software for peak alignment, normalization, and metabolite identification. We utilize extensive metabolic libraries to annotate as many features as possible, turning raw signals into biological insights.
Flux Modeling and Strain Ranking
The final stage involves integrating the data into metabolic models. We rank the candidate strains based on criteria such as precursor availability, energy charge, and minimal byproduct formation. A report is delivered, providing a clear recommendation for the best-performing chassis.
Publication Data
DoI: 10.3390/microorganisms11071855
Journal: Microorganisms
IF: 4.2
Published: 2023
Results: This study aims to enhance 1,3-propanediol (1,3-PDO) productivity in the non-model, non-solventogenic chassis Clostridium beijerinckii Br21 via genetic manipulation. The strain naturally converts glycerol (a biodiesel byproduct) to 1,3-PDO but lacks efficient genetic tools. The authors constructed a modular vector (pMTL83251_Ppta-ack_1,3-PDO_cluster) harboring the 1,3-PDO gene cluster (dhaB1, dhaB2, pduO, dhaT) and established a tailored electroporation protocol (adjusting cell concentration and 5-h post-electroporation recovery) for successful transformation. Overexpression of these genes increased 1,3-PDO productivity by 35% (0.27 vs. 0.20 mmol L-1 h-1 in the wild type) without altering final yield. The work expands genetic tools for Clostridium and provides insights into glycerol metabolism, supporting sustainable 1,3-PDO production from industrial waste.
Fig.1 Genes related to the reductive branch of glycerol fermentation in C. beijerinckii Br21. (Bortolucci, et al., 2023)
Applications
Pharmaceutical Glycoprotein Production
Identify yeast or mammalian chassis with optimized nucleotide sugar pools and minimal protease activity, ensuring high-titer production of monoclonal antibodies and therapeutic enzymes with human-like glycosylation patterns.
Human Milk Oligosaccharide (HMO) Synthesis
Screen microbial strains for their ability to utilize lactose and flip it into complex HMOs, identifying hosts that naturally minimize the production of interfering organic acids.
Biofuel and Specialty Chemical Engineering
Evaluate the metabolic robustness of unconventional yeast or bacterial strains under stress conditions (e.g., high ethanol concentrations) to select a chassis capable of sustained industrial fermentation.
Nutraceutical and Natural Product Biosynthesis
Map the metabolic pathways of rare sugar or antioxidant producers to find "sweet spots" where carbon flux is naturally high, reducing the need for extensive genetic over-engineering.
Advantages
Unparalleled Analytical Sensitivity
Our LC-MS/MS and GC-MS platforms detect metabolites at femtomolar levels, allowing us to see subtle metabolic shifts that other labs might miss, ensuring no high-potential strain is overlooked.
Comprehensive Metabolite Coverage
We don't just look at the "usual suspects." Our untargeted approach captures thousands of metabolic features, providing a truly holistic view of the chassis' internal physiological state.
Specialized Glyco-Metabolomics Focus
As experts in glycobiology, we have specialized protocols for detecting sugar-nucleotides and lipid-linked oligosaccharides, which are critical for any glycan-related chassis development project.
Actionable Bioinformatic Insights
We don't just hand you a list of metabolites. Our reports include pathway enrichment analysis and flux modeling that tell you why a strain is performing a certain way and how to improve it.
Frequently Asked Questions
Customer Review
"The metabolomics screening provided by CD BioGlyco was a turning point for our HMO project. We had three candidate strains that looked identical in terms of growth, but the MS data revealed that one had a much higher pool of GDP-fucose. This saved us months of trial-and-error engineering."
– A.T., Principal Scientist
"Working with CD BioGlyco was a seamless experience. Their expertise in glycobiology is evident in the way they interpret metabolomic data. They didn't just give us peaks; they gave us a roadmap for our next engineering cycle."
– B.R., Senior Researcher
"The speed and depth of the untargeted metabolomics service exceeded our expectations. We identified a metabolic byproduct that was inhibiting our yield, something we would never have found with standard HPLC methods."
CD BioGlyco's metabolomics-based chassis strain screening service provides the high-resolution data and expert insights necessary to transform your biomanufacturing vision into a high-yielding reality. By looking deep into the cellular metabolism, we ensure that your chosen host is perfectly primed for success. Please feel free to contact us to help you design the optimal screening strategy for your unique goals.
Reference
Bortolucci, J.; et al. Enhancing 1,3-propanediol productivity in the non-model chassis Clostridium beijerinckii through genetic manipulation. Microorganisms. 2023, 11: 1855.
For research use only. Not intended for any clinical use.
Fig.1 Genes related to the reductive branch of glycerol fermentation in C. beijerinckii Br21. (Bortolucci, et al., 2023)
